In a small pilot study with 8 ITP patients, we found that 6 of them had reduced levels of autoantibodies against platelet GPIIb and/or GPIIIa after the corticosteroid treatment. This evidence concerns the gene ITGA2B and autoimmune thrombocytopenic purpura.